Indivior Pharmaceuticals (INDV) Receivables - Other (2023 - 2025)

Indivior Pharmaceuticals has reported Receivables - Other for 3 years, with the latest figure at $2.0 million in Q4 2025.

• On a quarterly basis, Receivables - Other changed 0.0% year-over-year to $2.0 million in Q4 2025; TTM through Dec 2025 was $2.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.0 million, changed 0.0% from the prior year.
• Receivables - Other was $2.0 million for Q4 2025 at Indivior Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
• The five-year high for Receivables - Other was $2.0 million in Q4 2024, with the low at $1.0 million in Q4 2023.
• Average Receivables - Other over 3 years is $1.7 million, with a median of $2.0 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other soared 100.0% in 2024, then changed 0.0% in 2025.
• Over 3 years, Receivables - Other stood at $1.0 million in 2023, then jumped by 100.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
• The last three Receivables - Other figures came in at $2.0 million (Q4 2025), $2.0 million (Q4 2024), and $1.0 million (Q4 2023), per Business Quant data.